Pure red cell aplasia caused by antibody to erythropoietin successfully treated by cyclosporine administration [5]

American Journal of Hematology

Volumn 82, Issue 3, 2007, Pages 247-248

  Shinohara, Kenji ^a  

^a Yamaguchi Pref Central Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; ERYTHROPOIETIN ANTIBODY; NEUTRALIZING ANTIBODY; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ANTIBODY TITER; CHRONIC KIDNEY FAILURE; DISEASE COURSE; ERYTHROCYTE TRANSFUSION; HEMODIALYSIS; HUMAN; JAPANESE; LETTER; PRIORITY JOURNAL; PURE RED CELL ANEMIA; RADIOIMMUNOPRECIPITATION;

ANTIBODIES, MONOCLONAL; CYCLOSPORINE; ERYTHROPOIETIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RED-CELL APLASIA, PURE; TREATMENT OUTCOME;

EID: 33847670216     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20740     Document Type: Letter

References (3)

1. Shinohara K, Mitani N, Miyazaki M, et al. Pure red-cell aplasia caused by the antibody to recombinant erythropoietin, Epoetin-β, in a Japanese patient with chronic renal failure. Am J Hematol 2005;78:15-20.
2. Tacey R, Greway A, Smiell J, Power D, Kromminga A, Daha M, Casadevall N, Kelley M. The detection of anti-erythropoietin antibodies in human serum and plasma. Part I. Validation on the protocol for a radioimmunoprecipitation assay. J Immunological Methods 2003;283:317-329.
3. Bennett CL, Courmoyer D, Carson KR, et al. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: A follow-up report from the Research on Adverse Drug events and Reports (RADRA) Project. Blood 2005;106:3343-3347.